Please login to the form below

Not currently logged in
Email:
Password:

Qtern

This page shows the latest Qtern news and features for those working in and with pharma, biotech and healthcare.

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

Among the other highlights from the CHMP meeting was the withdrawal by AstraZeneca (AZ) of an application to market diabetes combination Qtern (saxagliptin/dapagliflozin).

Latest news

  • AZ gets US approval for diabetes combo Qtern AZ gets US approval for diabetes combo Qtern

    The US FDA has approved AstraZeneca's Qtern, a two-drug therapy for type 2 diabetes, after rejecting the drug in 2015. ... Qtern is a fixed dose combination product based on the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) and SGLT2

  • 2017 set to be a 2017 set to be a "defining year" for AZ

    And two other new launches, Bevespi (glycopyrrolate and formoterol fumarate) for chronic obstructive pulmonary disease (COPD) and combination diabetes therapy Qtern (saxagliptin and dapagliflozin), will also help drive the recovery, said

  • EU clears AZ's FDA-rejected diabetes combination EU clears AZ's FDA-rejected diabetes combination

    Qtern is the first combination product of its kind approved in Europe and an important new treatment option to help patients reach their goals through powerful HbA1c reduction," she added. ... However the EU approval gives the company a chance to make

  • Gilead, Merck get CHMP backing for new hep C combinations Gilead, Merck get CHMP backing for new hep C combinations

    At its meeting last week the CHMP also gave a green light to AstraZeneca's DPP-4 inhibitor/SGLT2 inhibitor combination Qtern (saxagliptin/dapagliflozin) as a treatment for type 2 diabetes.

More from news
Approximately 3 fully matching, plus 2 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics